Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study

Hassan, M.; Duarte, Raquel; Mabayoje, V. O.; Dickens, Caroline; Lasisi, Akeem O.; Naicker, Saraladevi

doi:10.1186/s12882-020-02082-3

Cited by 4 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, efforts are being made to implement pharmacogenomics-guided treatment in Nigeria. Currently, pharmacogenomics testing is being used to evaluate the prevalence of genetic polymorphism among people living with Human Immunodeficiency Virus (HIV) who are receiving highly active antiretroviral therapy [ 18 , 19 ]. The findings from these ongoing studies are expected to guide the implementation of pharmacogenomics services into patient care.…”

Section: Introductionmentioning

confidence: 99%

Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study

Abubakar

Subramaniam

Ayinla³

et al. 2022

J of Pharm Policy and Pract

View full text Add to dashboard Cite

Objectives To evaluate knowledge, attitude and perception of community pharmacists towards pharmacogenomics services. Methods A cross-sectional study was conducted among community pharmacists in two cities in Northern Nigeria using a self-administered, validated and pre-tested questionnaire. The data were collected from December 2021 to February 2022 and were analysed using both descriptive and inferential analyses. Results A total of 161 completed questionnaires were included in this study (response rate was 61.9%). Most of the respondents were males (59.0%). Only 25.5% had previous pharmacogenomics training but 90.1% indicated an interest in attending pharmacogenomics training in the future. Overall, respondents had moderate knowledge of pharmacogenomics with higher knowledge score found among those who had previous pharmacogenomics training (11.9 ± 1.7 vs 10.5 ± 2.4; p = 0.001), and those with postgraduate qualification (11.7 ± 1.9 vs 10.7 ± 2.3; p = 0.028). The mean attitude score was 6.8 ± 2.0 out of 10.0 indicating a good attitude towards pharmacogenomics services. Those with previous training (8.1 ± 1.7 vs 6.2 ± 1.9; p < 0.001) and those with postgraduate qualification (7.2 ± 2.3 vs 6.6 ± 1.9; p = 0.042) had better attitude towards pharmacogenomics services. The median perception score was 34.0 out of 45.0, indicating a positive perception towards pharmacogenomics. There was a better perception among those with previous pharmacogenomics training (40.0 [21–45] vs 34.0 [0–45]; p = 0.002) and those with postgraduate qualifications (39.0 [0–45] vs 34.0 [21–45]; p = 0.010). Barriers to the implementation of pharmacogenomics included lack of knowledge (89.4%), lack of guidelines (87.5%) and lack of reimbursement (81.4%). Conclusion Community pharmacists have a moderate knowledge, a good attitude and a positive perception towards pharmacogenomics services. Those with previous pharmacogenomics training and those with postgraduate qualifications had better knowledge, attitude and perception towards pharmacogenomics services. Lack of knowledge, lack of guidelines and lack of reimbursement were the major barriers to the implementation of pharmacogenomics services in community pharmacies in Nigeria. Pharmacogenomics should be included in pharmacy training curricula to prepare pharmacists for the provision of pharmacogenomics services. Development of local guidelines and a robust reimbursement plan for pharmacogenomics services is recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study

Abubakar

Subramaniam

Ayinla³

et al. 2022

J of Pharm Policy and Pract

View full text Add to dashboard Cite

show abstract

“…There has been an equipoise on the safety pro le of TDF, following the emergence of case series and studies that report features of RTD among patients on TDF. (7,8,(16)(17)(18)(19)(20)(21)(22)(23)(24)34). Histological renal changes associated with TDF are not uncommon (36).…”

Section: Discussionmentioning

confidence: 99%

“…TDF mainly affects the proximal renal tubule, and studies have reported the presence of tubular proteinuria, urinary phosphate wasting and other parameters of renal tubular dysfunction resembling the Fanconi syndrome in PLHIV taking TDF-containing regimens (6, [17][18][19][20][21][22][23][24]. TDF renal toxicity occurs as early as 3 to 6 months (25) and is thought to have the spontaneous resolution in 24 months (6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Renal Tubular Dysfunction Among People Living with HIV on Tenofovir Disoproxil Fumarate in Uganda: A Hospital-Based Cross-Sectional Study

Ng'umbi

Nuwagira

Kanyesigye

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Tenofovir Disoproxil Fumarate (TDF), the most commonly prescribed antiretroviral drug globally is associated with renal tubular dysfunction (RTD) whose magnitude is poorly understood in resource-limited settings. Our goal was to describe the prevalence and factors associated with renal tubular dysfunction in Uganda's people living with HIV(PLHIV) taking TDF-containing regimens. Methods We enrolled adult PLHIV receiving TDF-containing antiretroviral regimens from the HIV clinic at Mbarara Regional Referral Hospital. Socio-demographic, clinical and laboratory data were collected from each participant. Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) formula was used to estimate glomerular filtration rate (eGFR) and participants who had any two of, raised urinary excretion of phosphate, uric acid and glycosuria in non-diabetic normal glycemic were said to have renal tubular dysfunction. Logistic regression analysis was done to identify the factors that were independently associated with renal tubular dysfunction. Results Of the 145 participants enrolled, 84 (57.9%) were female, and the mean age was 46 (± 9) years. The mean serum creatinine was 0.77 (± 0.12) mg/dl and the mean eGFR of 112 (±24) mL/min/1.73m2. A total of 116/145 (80%) participants had at least one abnormality in parameters of tubular dysfunction; 26 (17.9%) and 3 (2.1%) of the participants had a combination of two or more parameters, respectively. In our study, the prevalence of renal tubular dysfunction was 20% (29/145) (95% CI 14.2-27.3). Female gender was statistically significantly associated with tubular dysfunction, adjusted odds ratio (AOR): 2.75, 95% (CI. 1.05-7.19), p=0.03. Conclusion The prevalence of renal tubular dysfunction is high and can occur in patients receiving TDF despite normal serum creatinine. We recommend using urinary abnormalities other than isolated serum creatinine in the detection of renal tubular dysfunction.

show abstract

“…The apical membrane transporters multidrug resistance protein (MRP-4) and MRP-2 then release the drug into the tubular lumen. (Multidrug resistance proteins, encoded by ATP-binding cassette transporter sub-family C member (ABCC4) and ABCC2 genes [ 3 , 4 ]).…”

Section: Introductionmentioning

confidence: 99%

Tenofovir-Induced Renal Dysfunction Among HIV-Infected Patients: A Systematic Review

Shivakumar,

Burra,

Shahid

et al. 2023

Cureus

View full text Add to dashboard Cite

Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug widely used as part of antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV-1) infection. Negative effects of tenofovir include impaired kidney function, especially with long-term use. In studies conducted among HIV-positive individuals, we found evidence of extensive kidney damage associated with TDF use. Despite the therapeutic importance of this consequence, its continued use in ART regimens was not contraindicated. The therapeutic and long-term effects of TDF are a major concern. However, in countries or settings where resources are limited and renal function monitoring cannot be ensured, screening methods to detect ART-related renal failure are still supported by data. Therefore, it is safe to re-evaluate the use of TDF-based ART. However, adherence to guidelines may be hampered by insufficient laboratory testing in low- and middle-income countries. More research is also needed among people under 18 years of age and pregnant and breastfeeding mothers.

show abstract

Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study

Cited by 4 publications

References 34 publications

Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study

Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study

Renal Tubular Dysfunction Among People Living with HIV on Tenofovir Disoproxil Fumarate in Uganda: A Hospital-Based Cross-Sectional Study

Tenofovir-Induced Renal Dysfunction Among HIV-Infected Patients: A Systematic Review

Contact Info

Product

Resources

About